Infliximab ELISA Kit (Remsima^®) (ab237647) has been developed for specific quantification of Infliximab concentration in human serum or plasma with high sensitivity and reproducibility. The density of color is proportional to the amount of Infliximab captured from the samples and can be quantified when compared with standard curve.

Infliximab (CT-P13) (Remsima^®) is a chimeric monoclonal antibody and used to treat auto-immune disorders. Infliximab reduces the amount of active human tumor necrosis factor alpha (hTNFα) in the body by binding to it and preventing it from signaling the receptors for TNFα on the surface of various cell types. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. In controlled trials, clinical response rates of 20-40% have been achieved with above-mentioned regimens in Crohn’s disease and rheumatoid arthritis. However, the therapeutic benefits must be balanced against the risk of a variety of severe adverse events such as severe infections including tuberculosis, hepatotoxicity, infusion reactions, serum sickness-like disease and lymphoma.